Navigation Links
Regado Biosciences, Inc. Adds Global Pharmaceutical Business Veteran to Board of Directors
Date:11/18/2013

BASKING RIDGE, N.J., Nov. 18, 2013 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced the appointment of Pierre Legault, MBA, CA, CPA, to its Board of Directors, where he will serve as Chairman of the audit committee. 

Mr. Legault has extraordinarily broad executive management experience, including more than 30 years spent executing creative financing strategies, driving corporate development, and constructing value-driving transactions for international biotechnology and pharmaceutical companies.  In addition, Mr. Legault has significant experience serving on the board of directors and audit committees of public companies.

Mr. Legault is currently CEO of NephroGenex, a late-stage biotech company, and was previously Executive Chairman.  He is also President and CEO of Stone Management LLC, a firm focused in the areas of business development and board assistance.  From 2009 to 2012, he held leadership positions at Astellas Pharmaceuticals and its legacy companies, including Chief Executive Officer of Prosidion Ltd., and Executive VP, CFO and Treasurer of OSI Pharmaceuticals.  From January 2006 to December 2008, Mr. Legault worked for Rite Aid Corporation, a Fortune 500 publicly traded pharmaceutical retail company, most recently as senior executive vice president and chief administrative officer.  Prior to Rite Aid Corporation, Mr. Legault held several senior positions over 15+ years at Sanofi-Aventis and predecessor companies, serving most recently as Worldwide President of a large, global dermatology business unit.

In addition, Mr. Legault has served on several public, private and nonprofit company boards and audit committees, including Forest Laboratories, Inc., on which he serves currently as audit committee Chairman.  Prior board positions include OSI Investment Holdings GMBH (Chairman), Cyclacel Pharmaceutical Inc., PJC Inc., as well as other private boards.  Mr. Legault studied at the Harvard Business School in an executive masters program and he received his MBA from McGill University and his BAA from University of Montreal (HEC).  He also holds CA and CPA degrees.

Mr. Legault stated, "Throughout my career I have chosen board appointments very carefully, and I see a tremendous opportunity in Regado.  As the company continues to drive toward clinical success with REG1, I look forward to offering my expertise and guidance."

Dennis Podlesak, MBA, Regado's Board Chairman, stated, "We are very pleased to add Mr. Legault to our board of directors and as our audit committee Chairman.  We believe his specific expertise in this role will be a valuable asset for Regado, as will his impressive background in running international pharmaceutical companies across the full spectrum of clinical and commercial development." 

ABOUT REGADO BIOSCIENCES
Regado Biosciences, Inc. is a biopharmaceutical company focused on the development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications.  Regado is pioneering the development of two-component drug systems consisting of a therapeutic aptamer and its specific active control agent. The company's lead product candidate, REG1, is a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen.  REG1 is being developed for use in patients with a wide variety of acute coronary syndromes, or ACS, undergoing a percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. Regado's actively controllable product candidates have the potential to improve patient outcomes, enhance the patient experience and reduce overall treatment costs.  More information can be found at www.regadobio.com.

For more information on REGULATE-PCI, please visit: 
http://www.clinicaltrials.gov/ct2/show/NCT01848106?term=Regado&rank=1

Contact: 
Tiberend Strategic Advisors, Inc.

Investors - Joshua Drumm, Ph.D. 
jdrumm@tiberend.com; (212) 375-2664

Media - Andrew Mielach 
amielach@tiberend.com; (212) 375-2694


'/>"/>
SOURCE Regado Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regado Biosciences, Inc. Announces Third Quarter 2013 Results
2. Regado Biosciences, Inc. Announces Closing of Initial Public Offering
3. Regado Biosciences, Inc. Announces Pricing of Initial Public Offering
4. Regado Biosciences, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York, NY
5. Regado Biosciences, Inc. to Present at the UBS Global Life Sciences Conference 2012 in New York, NY
6. Regado Biosciences, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference in Boston, MA
7. Regado Biosciences, Inc. to Present at the 2012 Wedbush PacGrow Life Sciences Conference in New York, NY
8. Pressure BioSciences, Inc. Discusses Record Third Quarter Revenue, Strong Fourth Quarter Guidance, Significant Progress on New Instrument Systems, and Expectation to Pay-Off All Outstanding Convertible Notes at the SeeThruEquity Financial Conference
9. Jeeven BioSciences, Inc. Announces the Release of its Neuro-X(TM) Serum Free and Xeno Free Tissue Culture Media
10. SeeThruEquity, LLC Initiates Coverage on Pressure BioSciences, Inc.
11. Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... PUNE, India , January 24, 2017 /PRNewswire/ ... Market Research, titled, "Cold Chain Logistics Market by Application ... Frozen Dessert, Meat, Fish & Sea Food, Drugs & ... Forecasts, 2014-2022," projects that the global cold chain logistics ... growing at a CAGR of 16% (2016 to 2022). ...
(Date:1/24/2017)... , Jan. 24, 2017 Regeneron Pharmaceuticals, Inc. ... Public today recognized 40 finalists in the Regeneron Science ... and math competition for high school seniors. Finalists were ... of their research projects. The finalists will ... from March 9-15 to undergo a rigorous judging process ...
(Date:1/24/2017)... 24, 2017 Research and Markets has announced ... Trends - Product, Material - Forecast to 2025" report to ... ... a CAGR of around 5.4% over the next decade to reach ... trends that the market is witnessing include 3D medical printing is ...
Breaking Medicine Technology:
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... This Saturday, ... & magic, plus a very special performance by Alabama Symphony Orchestra musicians Yifan Zhou, ... their specialties, such as dim sum, and exhibitors offer a look at Chinese games, ...
(Date:1/24/2017)... ... 2017 , ... Inspiration, Community & Mentorship – Top Students ... Fordham Institute’s High Stakes for High Achievers offer recommendations for how ... high-achieving students as a subgroup and reporting their results separately. Top students and ...
(Date:1/24/2017)... Pass, OR (PRWEB) , ... January 24, 2017 ... ... Gerald H. Pollack, Ph.D., http://www.faculty.washington.edu/ghp , Sharon Kleyne, the nation’s foremost ... of Water, Global Climate Change and Your Health on Voice America, once again ...
(Date:1/24/2017)... Scottsdale, AZ (PRWEB) , ... January 24, 2017 , ... ... than 30 lives in the last month. Yellow fever is primarily spread through contact ... the health community’s focus on how to prevent its spread. , According to multiple ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... to topics like finances, friendship, marriage, leadership, gossip, prostitution, adultery, anger, and common ... Publishing authors, Dr. Judith Coats and Dr. David Coats. In September of 1983, ...
Breaking Medicine News(10 mins):